Cart
sales@molnova.com
BCI
CAS No. 1245792-51-1
BCI( (E)-BCI )
Catalog No. M22447 CAS No. 1245792-51-1
BCI is an allosteric inhibitor of dual-specificity phosphatase (DUSP; EC50s: 13.3 and 8.0 μM for DUSP6 and DUSP1 in cells) and does not inhibit DUSP5.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 113 | In Stock |
|
| 10MG | 186 | In Stock |
|
| 25MG | 298 | In Stock |
|
| 50MG | 447 | In Stock |
|
| 100MG | 651 | In Stock |
|
| 500MG | 1368 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBCI
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCI is an allosteric inhibitor of dual-specificity phosphatase (DUSP; EC50s: 13.3 and 8.0 μM for DUSP6 and DUSP1 in cells) and does not inhibit DUSP5.
-
DescriptionBCI is an allosteric inhibitor of dual-specificity phosphatase (DUSP; EC50s: 13.3 and 8.0 μM for DUSP6 and DUSP1 in cells) and does not inhibit DUSP5.
-
In VitroWestern Blot Analysis Cell Line:RAW264.7 macrophage cells Concentration:100 ng/mL Incubation Time:24 hours Result:Showed DUSP6 protein downregulation.RT-PCR Cell Line:RAW264.7 macrophage cells Concentration:0-1 nM Incubation Time:24 hours Result:Inhibited the expression of IL-1β and IL-6 mRNA in LPS-activated macrophages.
-
In Vivo——
-
Synonyms(E)-BCI
-
PathwayMetabolic Enzyme/Protease
-
TargetPhosphatase
-
Recptorphosphatase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1245792-51-1
-
Formula Weight317.42
-
Molecular FormulaC22H23NO
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (393.80 mM; Need ultrasonic)
-
SMILESO=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45.
molnova catalog
related products
-
SHP099
SHP099 free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM). SHP099 shows dose-dependent pathway inhibition and antitumor activity in xenograft models.
-
DJ001
DJ001 is a highly specific, selective, and non-competitive protein tyrosine phosphatase σ (PTPσ) inhibitor with an IC50 of 1.43 μM, and it promotes the regeneration of hematopoietic stem cells.
-
IFB-088 acetate
IFB-088 acetate, a benzyl guanidine derivative, is used to treat diseases and cancers associated with the PPP1R15A pathway and associated with protein misfolding stress, Examples include tau disease.
